Repligen (RGEN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Repligen

NasdaqGS•Healthcare•Medical Instruments & Supplies

$164.68-0.37(<0.01%)After hours

Market Cap

$9.98B

P/E

240.3x

P/S

12.7x

P/B

4.7x

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

How this company scores

GoodMetricSide Score: 73/100

Strongest: Growth (22/25); weakest: Profitability (12/25).

Profitability12/25

Growth22/25

Balance Sheet & Red Flags18/25

Cash & Earnings Quality21/25

Strengths

Growing revenueRising earningsLow leverageCash-backed earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 240.3x5y range 0.1x – 240.3x

Currently above its 15-quarter median.

P/S · 12.7x5y range 0.0x – 26.6x

Currently above its 20-quarter median.

P/B · 4.7x5y range 0.0x – 9.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Share Dilution

Red Flag

Shares outstanding increased 100624.8% — significant dilution, likely from stock compensation or capital raises.

Price & Volume

Market Cap $9.98B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $785.10M
Q. Revenue: $204.13M
TTM EBITDA: $183.48M
TTM Op. Income: $64.61M
Q. Op. Income: $13.98M
TTM Net Income: $41.54M
Q. Net Income: $5.01M
EPS: $0.09
Shares Out.: $56.42M

$785.10M in TTM revenue grew 15.4% YoY, reaching $204.13M last quarter. TTM EBITDA of $183.48M and TTM operating income of $64.61M show growth is flowing through to the bottom line. TTM net income of $41.54M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 53.9%
EBITDA Margin: 16.2%
Op. Margin: 6.8%
Net Margin: 2.5%

Op. margin of 6.8% is down 0.8% YoY — costs are rising relative to revenue. Net margin at 2.5% and gross margin of 53.9% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 240.3x
P/S Ratio: 12.7x
P/B Ratio: 4.7x

At 240.3x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 12.7x and P/B of 4.7x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 4 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $2.95B
Cash: $606.78M
Long-Term Debt: $551.05M
Book Value: $2.11B
D/E Ratio: 0.3
Debt/EBITDA: 16.7

With $2.95B in assets and $551.05M in long-term debt, D/E is 0.3and book value is $2.11B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $32.77M
TTM Free Cash Flow: $111.97M
FCF Margin: 14.3%
FCF / Net Income: 2.7

TTM FCF of $111.97M on $32.77M in operating cash flow. The FCF / Net Income ratio of 2.7x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.